SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
"Take a peek at the unique PR campaign now being run by the pharmaceutical industry," Hightower writes. (Photo: StockMonkeys.com)
If you wonder why Congress critters keep ignoring what the people want them to do -- while doing things that people don't want them doing -- take a peek at the unique PR campaign now being run by the pharmaceutical industry.
The public is dismayed and disgusted by the flagrant greed of drugmakers that are shamefully zooming the prices of medicines into the stratosphere, turning necessities into unaffordable luxuries. As a result, there's a growing demand for Congress to take action to stop the industry's out-of-control price gouging.
To counter this, drug companies have launched a massive advertising campaign. They're running ads on radio, in print, and on Facebook and Twitter painting themselves as the good guys.
Yet you probably haven't seen or heard any of them. That's because drug chieftains don't care what you and I think. Moreover, they know they couldn't possibly persuade us to let them keep jacking up their prices.
Instead, their "public" relations effort has made the odd and seemingly counterproductive move of sidestepping the actual public to narrowly target a very tiny audience.
As Celgene executive Bob Hugin arrogantly put it: "We've identified 7,000 Americans who matter." The other 330 million of us, apparently, are nobodies.
"We're focusing on those in policy positions," Hugin sniffed, "to fight structural issues." By that, he means convincing Congress not to reform the present pricing structure of monopolistic drugmakers, whose guiding corporate ethic is "bleed 'em for all they've got."
So this is a surreptitious PR campaign meant to reach only the eyes and ears of policy elites. The goal is to have Congress -- once again -- ignore what the people want it to do, thus allowing the corporate few "who matter" to keep fleecing the rest of us.
Political revenge. Mass deportations. Project 2025. Unfathomable corruption. Attacks on Social Security, Medicare, and Medicaid. Pardons for insurrectionists. An all-out assault on democracy. Republicans in Congress are scrambling to give Trump broad new powers to strip the tax-exempt status of any nonprofit he doesn’t like by declaring it a “terrorist-supporting organization.” Trump has already begun filing lawsuits against news outlets that criticize him. At Common Dreams, we won’t back down, but we must get ready for whatever Trump and his thugs throw at us. As a people-powered nonprofit news outlet, we cover issues the corporate media never will, but we can only continue with our readers’ support. By donating today, please help us fight the dangers of a second Trump presidency. |
If you wonder why Congress critters keep ignoring what the people want them to do -- while doing things that people don't want them doing -- take a peek at the unique PR campaign now being run by the pharmaceutical industry.
The public is dismayed and disgusted by the flagrant greed of drugmakers that are shamefully zooming the prices of medicines into the stratosphere, turning necessities into unaffordable luxuries. As a result, there's a growing demand for Congress to take action to stop the industry's out-of-control price gouging.
To counter this, drug companies have launched a massive advertising campaign. They're running ads on radio, in print, and on Facebook and Twitter painting themselves as the good guys.
Yet you probably haven't seen or heard any of them. That's because drug chieftains don't care what you and I think. Moreover, they know they couldn't possibly persuade us to let them keep jacking up their prices.
Instead, their "public" relations effort has made the odd and seemingly counterproductive move of sidestepping the actual public to narrowly target a very tiny audience.
As Celgene executive Bob Hugin arrogantly put it: "We've identified 7,000 Americans who matter." The other 330 million of us, apparently, are nobodies.
"We're focusing on those in policy positions," Hugin sniffed, "to fight structural issues." By that, he means convincing Congress not to reform the present pricing structure of monopolistic drugmakers, whose guiding corporate ethic is "bleed 'em for all they've got."
So this is a surreptitious PR campaign meant to reach only the eyes and ears of policy elites. The goal is to have Congress -- once again -- ignore what the people want it to do, thus allowing the corporate few "who matter" to keep fleecing the rest of us.
If you wonder why Congress critters keep ignoring what the people want them to do -- while doing things that people don't want them doing -- take a peek at the unique PR campaign now being run by the pharmaceutical industry.
The public is dismayed and disgusted by the flagrant greed of drugmakers that are shamefully zooming the prices of medicines into the stratosphere, turning necessities into unaffordable luxuries. As a result, there's a growing demand for Congress to take action to stop the industry's out-of-control price gouging.
To counter this, drug companies have launched a massive advertising campaign. They're running ads on radio, in print, and on Facebook and Twitter painting themselves as the good guys.
Yet you probably haven't seen or heard any of them. That's because drug chieftains don't care what you and I think. Moreover, they know they couldn't possibly persuade us to let them keep jacking up their prices.
Instead, their "public" relations effort has made the odd and seemingly counterproductive move of sidestepping the actual public to narrowly target a very tiny audience.
As Celgene executive Bob Hugin arrogantly put it: "We've identified 7,000 Americans who matter." The other 330 million of us, apparently, are nobodies.
"We're focusing on those in policy positions," Hugin sniffed, "to fight structural issues." By that, he means convincing Congress not to reform the present pricing structure of monopolistic drugmakers, whose guiding corporate ethic is "bleed 'em for all they've got."
So this is a surreptitious PR campaign meant to reach only the eyes and ears of policy elites. The goal is to have Congress -- once again -- ignore what the people want it to do, thus allowing the corporate few "who matter" to keep fleecing the rest of us.